课题基金 / 基金详情

Development-HTS Assay-Identify Specific Alternative(RMI)

Development-HTS Assay-Identify Specific Alternative(RMI)
开发-HTS 检测-确定特定替代方案(RMI)
批准号:
7020414
负责人:
Luca Cartegni
金额:
$20.93万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-30 至 2007-08-31

项目摘要

项目成果

Luca Cartegni的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The objective of this project is to develop robust assays that will allow real-time monitoring and quantification of specific alternative splicing events in living cells, and to adapt them for high throughput screening (HTS) against libraries of small compounds. Deregulation of alternative splicing patterns is frequently associated with several neurodegenerative and other genetic diseases and is a common occurrence in most cancers. The ability to re-direct splicing events to correct such splicing defects or to force the expression of alternative splicing isoform with potential beneficial effects would provide a valuable tool to investigate the roles and functions of specific alternative splicing isoforms, and it will open wide possibilities for novel therapeutic approaches. We plan to develop a set of minigene constructs in which the expression of a transiently transfected fluorescent reporter protein will quantitatively depend on a specific splicing event. The initial testing will investigate alternative splicing events in STAT3 and BRCA1, but the setup will be readily transferable to different systems. The assay will be initially performed in 96 well plates and used in low-to-medium throughput experiments to identify and characterize cis-elements and trans acting factors that regulate these splicing events, by means of systematic over-expression and/or knockdown of splicing factors combined with substrate mutagenesis. Multiple fluorescent variants will be tested in various combinations using the Amersham INCell analyzer, to eventually develop a multicolor protocol to simultaneously assess different splicing events in individual cells, along with appropriate counter screenings and validation procedures. The protocol will be optimized to 384 well microtiter plates and will be suitable to HTS of large small molecule libraries.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Refractory EGFR-Driven Tumors By Induction Of Dominant-Negative EGFR Splicing Variants
  • 批准号:
    10062910
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    Luca Cartegni
  • 依托单位:
Targeting Refractory EGFR-Driven Tumors By Induction Of Dominant-Negative EGFR Splicing Variants
Therapeutic potential of antitumorigenic soluble MET variants induced by splicing interference
  • 批准号:
    10062886
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2017
  • 负责人:
    Luca Cartegni
  • 依托单位:
Therapeutic potential of antitumorigenic soluble MET variants induced by splicing interference
海外基金